<progress id="drqnt"><track id="drqnt"></track></progress><var id="drqnt"><source id="drqnt"><meter id="drqnt"></meter></source></var>
  1. <button id="drqnt"><object id="drqnt"></object></button>

          <button id="drqnt"><object id="drqnt"></object></button>
        1. <button id="drqnt"><acronym id="drqnt"></acronym></button><dd id="drqnt"><pre id="drqnt"></pre></dd>
          <em id="drqnt"><ruby id="drqnt"><u id="drqnt"></u></ruby></em>
          1. <dd id="drqnt"><noscript id="drqnt"></noscript></dd>
            <li id="drqnt"></li>
            1. <legend id="drqnt"></legend>

              Monoclonal antibody customization

                    There are millions of different B lymphocyte lines in animal spleen. After rearrangement, B lymphocytes with different genes synthesize different antibodies. When the body is stimulated by antigen, many determinants on antigen molecules activate B cells with different genes respectively. Hybridoma cells are formed by fusing immune animal B lymphocytes and myeloma cells using lymphocyte hybridoma technology. Hybridoma cells derived from a single B cell with antibody secretion function and unlimited reproduction are selected through HAT screening, ELISA antibody detection and limited dilution cloning. The cell secretes and produces highly specific antibodies that are very homogeneous, have the same structure and amino acid sequence, and are targeted at only one antigen, namely monoclonal antibodies.

                    The biggest advantage of monoclonal antibody is its specificity, uniformity, high efficiency and unlimited supply. It has shown great vitality in basic research and clinical medicine in immunology, medicine, biology and other fields, including diagnosis, prevention and treatment of diseases (including cancer).



              Service number Service content service standard cycle
              SY-2002A 多肽→單抗 1.2-5株雜交瘤細胞株; 2.每株細胞提供2-5mg抗體; 3.抗體ELISA≥80,000; 16-20周
              SY-2001A 蛋白→單抗 1.2-5株雜交瘤細胞株; 2.每株細胞提供2-5mg抗體; 3.抗體ELISA≥80,000; 16-20周
              SY-2003A 修飾性多肽→單抗(磷酸化/甲基化/乙?;?其它修飾) 16-20周
              SY-2004A 小分子化合物→單抗 1.1-3株雜交瘤細胞株; 2.每株細胞提供2-5 mg抗體; 3.抗體針對小分子偶聯物Elisa效價大于80000,同時抗體與小分子偶聯物的結合能夠被小分子化
              SY-2002 多肽單抗 1.2-5株雜交瘤細胞株; 2.每株細胞提供2-5mg抗體; 3.抗體ELISA≥80,000; 20-26周
              SY-2003 磷酸化多肽單抗 1.2-5株雜交瘤細胞株; 2.每株細胞提供2-5 mg抗體; 3.磷酸化多肽抗體ELISA效價大于80,000; 4.磷酸化多肽與非磷酸化多肽效價區分大于16倍(ELISA、Dot Blot); 20-26周
              SY-2004 小分子化合物單抗 1.1-3株雜交瘤細胞株; 2.每株細胞提供2-5 mg抗體; 3.抗體針對小分子偶聯物Elisa效價大于80000,同時抗體與小分子偶聯物的結合能夠被小分子化 20-26周
              SY-2005 蛋白檢測配對單抗 1.2-5株雜交瘤細胞株; 2.1對ELISA配對檢測抗原的抗體,包被抗體和標記抗體各5mg; 22-30周
              SY-2001 蛋白單抗 1.2-5株雜交瘤細胞株; 2.每株細胞提供2-5mg抗體; 3.抗體ELISA≥80,000; 70天
              SY-2001 蛋白單抗 1.2-5株雜交瘤細胞株; 2.每株細胞提供2-5mg抗體; 3.抗體ELISA≥80,000;
              Collect from
              鄂ICP備19022221號-2 Trigoats Co., Ltd.